Thursday, June 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

MRIGlobal Wins Contract to Develop Revolutionary Diagnostic System

by Global Biodefense Staff
February 25, 2015
Genomic Sequencing

The Defense Threat Reduction Agency (DTRA) has awarded a $14.8 million contract to MRIGlobal for development of an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.

MRIGlobal’s proposed Sample-to-Sequence system will take clinical samples (blood or saliva, for example) and generate high-quality whole genome sequences of bacteria and viruses. The diagnostic tool will be able to identify a broad range of human pathogens, from a single sample with particular emphasis on emerging pathogens and those not identifiable by available rapid diagnostic methods.

The Sample-to-Sequence system has the potential to revolutionize clinical diagnostics, providing faster diagnoses results to enable better health outcomes. A clinician could send a single sample to a laboratory for sequencing, and the genomes uncovered in the sample will be identified against a developed database of microorganisms capable of causing infectious diseases.

“This is a revolutionary approach,” said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal. “Today, each test requires a unique sample, and certain procedures such as blood cultures can take a week to generate data. Sample-to-Sequence will provide rapid answers within 24 hours, giving actionable data to improve diagnoses and lead to better public health outcomes.”

The three-year DTRA contract will enable the program to generate clinical data that will be used to apply for FDA approval and ultimate release to the commercial market.

MRIGlobal will provide analysis of technology and selection of key components addressing sample preparation, next-generation sequencing, and bioinformatics. The organization will also lead the systems engineering and integration, and testing, in preparation for regulatory reviews and the post-contract commercialization of the system.

“MRIGlobal will integrate a diverse team of experts from leading commercial and government entities in this development,” said Michael Cassler, Ph.D., Director of MRIGlobal Molecular Diagnostics. “We will deploy a ‘Gold Standard’ pathogen database to generate diagnostic calls as well as draft genomes and antibiotic resistant profiles from the samples.”

“The ultimate goal is a new tool that clinicians worldwide can use to quickly and accurately identify deadly infectious disease-causing microorganisms, allowing for more rapid and accurate treatment to ultimately save lives,” Cassler said.

Tags: AwardsBioinformatics

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC